Recursion Pharmaceuticals, Inc.
3.215USD
-0.2250 (-6.54%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 39.8M | 44.6M | 58.8M | 74.7M | 42.7M | 56.3M |
| Q1 | 5.3M | 12.1M | 13.8M | 14.7M | 6.5M | — |
| Q2 | 7.7M | 11.0M | 14.4M | 19.2M | 7.7M | — |
| Q3 | 13.2M | 10.5M | 26.1M | 5.2M | 14.2M | — |
| Q4 | 13.7M* | 10.9M* | 4.5M* | 35.5M* | 16.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.36 | -1.58 | -1.69 | -1.44 | -.923 | -.895 |
| Q1 | -.330 | -.340 | -.390 | -.500 | -.220 | — |
| Q2 | -.380 | -.380 | -.400 | -.410 | -.250 | — |
| Q3 | -.350 | -.430 | -.340 | -.360 | -.229 | — |
| Q4 | -.328* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.447* |
| -.652* |
| -.242* |
| -.218 |
| — |